Measuring Health-Related Quality of Life in Patients With Hepatobiliary Cancers: The Functional Assessment of Cancer Therapy–Hepatobiliary Questionnaire

Heffernan, Nancy; Cella, David; Webster, Kimberly; Odom, Linda; Martone, Mary; Passik, Steven D.; Bookbinder, Marilyn; Fong, Yuman; Jarnagin, William R.; Blumgart, Leslie H.

doi:10.1200/jco.2002.07.093

Cited by 224 publications

(203 citation statements)

References 34 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…18,23,24,37 We used both the FACT-G and FACT-Hep questionnaires, which have an excellent test-retest reliability, and high internal consistency are easy to complete and have been validated for patients with pancreatobiliary cancers. [23][24][25][26] In addition to the general and disease-specific scores we also evaluated the F-TOI, a functional index that is a sensitive indicator of clinical outcome. 27 In the present study, data were analyzed to look for both statistical and clinical significance, which account for two different perspectives in HQOL interpretation.…”

Section: Discussionmentioning

confidence: 99%

“…FACT-G and FACT-Hep have been previously validated in cancer populations. [25][26][27] From these two questionnaires, three scores were obtained: the FACT-G score, which is the sum of the four subscales; the FACT-Hep, which is the sum of the FACT-G and the diseasespecific module (FACT-Hep), and the Trial Outcome Index (TOI), which is the sum of the physical, functional and disease-specific module. The TOI has been demonstrated to be a sensitive indicator of clinical outcome.…”

Section: Quality Of Life Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment

Crippa

Domínguez

Rodríguez

et al. 2008

Journal of Gastrointestinal Surgery

103

View full text Add to dashboard Cite

In pancreatic cancer patients, survival and palliation of symptoms should be balanced with social and functional impairment, and for this reason, health-related quality of life measurements could play an important role in the decision-making process. The aim of this work was to evaluate the quality of life and survival in 92 patients with different stages of pancreatic adenocarcinoma who underwent surgical and/or medical interventions. Patients were evaluated with the Functional Assessment of Cancer Therapy questionnaires at diagnosis and follow-up (3 and 6 months). At diagnosis, 28 patients (30.5%) had localized disease (group 1) and underwent surgical resection, 34 (37%) had locally advanced (group 2), and 30 (32.5%) metastatic disease (Group 3). NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptImprovement in quality of life was found in group 1, while in group 3, it decreased at follow-up (p = 0.03). No changes in quality of life in group 2 were found. Chemotherapy/chemoradiation seems not to significantly modify quality of life in groups 2 and 3. Median survival time for the entire cohort was 9.8 months (range, 1-24). One-year survival was 74%, 30%, and 16% for groups 1, 2, and 3 respectively (p = 0.001). Pancreatic cancer prognosis is still dismal. In addition to long-term survival benefits, surgery impacts favorably quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Quality Of Life Assessmentmentioning

confidence: 99%

Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment

Crippa

Domínguez

Rodríguez

et al. 2008

Journal of Gastrointestinal Surgery

103

View full text Add to dashboard Cite

show abstract

“…Health-related quality of life (HRQL) was self-rated by patients each month before their clinical review using two instruments: the FACT-Hep (Heffernan et al, 2002) and the 'Patient Disease And Treatment Assessment' form (Pt DATA Form). After the first month of treatment, patients also rated how aspects of their HRQL had changed, using a series of transition scales referred to here as the subjective Patient Benefit Form.…”

Section: Methodsmentioning

confidence: 99%

“…The FACT-Hep (Heffernan et al, 2002) is a validated 45-item self-rated questionnaire, incorporating the FACT-G questionnaire (27 items) (Cella et al, 1993), which covers multiple general aspects of HRQL, and an 18-item module specific for hepatobiliary cancer. Scores are calculated for four domains from the FACT-G: physical, social -family, emotional, and functional well-being.…”

Section: Methodsmentioning

confidence: 99%

Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide

Cebon

2006

Br J Cancer

View full text Add to dashboard Cite

Octreotide may extend survival in hepatocellular carcinoma (HCC). Forty-one per cent of HCCs have high-affinity somatostatin receptors. We aimed to determine the feasibility, safety, and activity of long-acting octreotide in advanced HCC; to identify the best method for assessing somatostatin receptor expression; to relate receptor expression to clinical outcomes; and to evaluate toxicity. Sixty-three patients with advanced HCC received intramuscular long-acting octreotide 20 mg monthly until progression or toxicity. Median age was 67 years (range 28 -81 years), male 81%, Child -Pugh A 83%, and B 17%. The aetiologies of chronic liver disease were alcohol (22%), viral hepatitis (44%), and haemochromatosis (6%). Prior treatments for HCC included surgery (8%), chemotherapy (2%), local ablation (11%), and chemoembolisation (6%). One patient had an objective partial tumour response (2%, 95% CI 0 -9%). Serum alpha-fetoprotein levels decreased more than 50% in four (6%). Median survival was 8 months. Thirty four of 61 patients (56%) had receptor expression detected by scintigraphy; no clear relationship with clinical outcomes was identified. There were few grade 3 or 4 toxicities: hyperglycaemia (8%), hypoglycaemia (2%), diarrhoea (5%), and anorexia (2%). Patients reported improvements in some symptoms, but no major changes in quality of life were detected. Long-acting octreotide is safe in advanced HCC. We found little evidence of anticancer activity. A definitive randomised trial would identify whether patients benefit from this treatment in other ways.

show abstract

“…This self-report questionnaire is appropriate for administration to patients at various stages in the disease process and has shown demonstrable reliability and validity in assessing patients physical and functional status. [18] The FACT-Hep contains specific subscales assessing physical well-being (seven questions), social/family well-being (seven questions), emotional well-being (six questions), functional well-being (seven questions), and additional concerns (18 questions). Patients answered to questions on a five-point scale ranging 0 (not at all) to 4 (very much).…”

Section: Qol Assessmentmentioning

confidence: 99%

Untitled

Murtezani

2017

AJP

View full text Add to dashboard Cite

Objective: The aim of this study is to assess the clinical effectiveness of folfirinox (Fol) compared with gemcitabine (Gem) on quality of life (QOL) that predicts survival in patients with Stage IV of pancreatic cancer. Materials and Methods: A total of 34 patients suffering from metastatic pancreatic adenocarcinoma were randomized into two groups, the Gem group (n = 17) and Fol group (n = 17). The first group was treated with Gem in a dose of 1000 mg/m 2 once weekly for 7 weeks, followed by 1 week of rest during the first cycle and subsequently 1000 mg/m 2 once weekly for 3 weeks followed by 1 week of rest. The second group was treated with Fol (oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , leucovorin 400 mg/m 2 , and fluorouracil 400 mg/m 2 bolus, followed by 2400 mg/m 2 on 46-h continuous infusion) once every 2 weeks. The QOL was measured by the functional assessment of cancer therapy (FACT)-hepatobiliary cancer scale. Results: Thirty-four of randomized patients completed the study, and there were no significant differences among the two groups at baseline demographic characteristics. Overall QOL, P value shows the significance of correlation for components of FACT in all scales between Fol-group and Gem-group. Median survival time for the entire cohort was 14.1 months for Fol-group compared to Gem-group which was 9.2 months. P value shows the significance of the correlation between survival rate and stage of tumor, in Fol-group versus Gem-group (P = 0.0001). Conclusions: We conclude that Fol significantly improves QOL, physical functioning and survival time in advanced pancreatic cancer patients in comparison with Gem.

show abstract

Measuring Health-Related Quality of Life in Patients With Hepatobiliary Cancers: The Functional Assessment of Cancer Therapy–Hepatobiliary Questionnaire

Abstract: The 45-item FACT-Hep can be used independently as a brief measure of disease-related symptoms and functioning. Alone or paired with the FACT-G, the HS has promise for use in assessing the disease-specific HRQL of patients with hepatobiliary cancers.

Cited by 224 publications

References 34 publications

Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment

Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment

Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide

Untitled

Contact Info

Product

Resources

About